hepat
c
viru
hcv
envelop
singlestrand
rna
viru
member
genu
hepaciviru
famili
worldwid
million
peopl
chronic
infect
hcv
thu
increas
risk
develop
seriou
lifethreaten
liver
current
standard
therapi
chronic
hepat
c
consist
combin
pegyl
interferon
ifn
ribavirin
unfortun
sustain
virolog
respons
therapi
limit
treat
thu
urgent
need
new
treatment
strategi
one
promis
approach
develop
small
molecul
target
specif
enzymat
activ
associ
viral
nonstructur
ns
protein
inhibit
specif
interact
viral
protein
viral
cellular
sever
select
inhibitor
includ
proteas
polymeras
inhibitor
clinic
directli
act
antivir
hcv
rapid
emerg
mani
resist
variant
report
vitro
clinic
set
success
approach
limit
drug
resist
implement
ration
design
drug
prerequisit
type
therapi
avail
multipl
select
drug
act
differ
target
glycopeptid
antibiot
ie
teicoplanin
vancomycin
use
treatment
gramposit
bacteri
antibacteri
activ
glycopeptid
antibiot
result
inhibit
one
mechan
involv
synthesi
bacteri
cell
wall
ie
inhibit
membran
protein
involv
transglycosyl
interact
daladala
moieti
prevent
transpeptid
natur
glycopeptid
antibiot
report
exert
antivir
activ
semisynthet
deriv
prove
endow
antivir
activ
retro
hiv
shown
semisynthet
aglycon
glycopeptid
potenti
interfer
viral
entri
compound
also
inhibit
coronaviru
replic
interf
earli
step
viral
life
report
vitro
antihcv
activ
aglycon
deriv
teicoplanin
novel
semisynthet
deriv
teicoplanin
aglycon
synthes
method
dissolv
dmso
mass
spectral
data
electrospray
mass
spectrometri
present
figur
mass
spectral
data
compound
recombin
purchas
schere
plough
heistopdenberg
belgium
hcv
proteas
inhibitor
nucleosid
polymeras
inhibitor
nonnucleosid
polymeras
inhibitor
benzofuran
describ
highli
permiss
cell
line
huh
kindli
provid
dr
f
v
chisari
scripp
research
institut
la
jolla
cell
carri
hcv
replicon
huh
mono
huh
huh
kindli
provid
professor
r
bartenschlag
univers
heidelberg
germani
cell
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
merelbek
belgium
supplement
heatinactiv
fetal
bovin
serum
integro
zaandam
netherland
nonessenti
amino
acid
iuml
penicillin
gibco
streptomycin
gibco
hygromycin
gibco
huh
mono
huh
huh
cell
cell
cultur
maintain
replicon
resist
panel
hcv
select
inhibitor
gener
previous
antivir
assay
perform
briefli
cell
seed
densiti
cell
per
well
cell
cultur
plate
dmem
contain
hygromycin
huh
huh
huh
mono
cell
respect
h
incub
medium
replac
fresh
dmem
without
serial
dilut
test
compound
replicon
rna
level
determin
revers
transcript
quantit
pcr
huh
cell
hcv
replic
quantifi
measur
firefli
luciferas
activ
cell
cultur
plate
safir
tecan
austria
highli
infecti
hcv
describ
delgrang
et
use
antivir
assay
total
huh
cell
per
well
cell
cultur
plate
incub
viru
specif
infect
specif
infect
ratio
hcv
rna
copi
number
focusform
unit
per
ml
time
serial
dilut
compound
follow
day
incub
medium
remov
cell
wash
lyse
extract
intracellular
rna
hcv
rna
quantifi
mean
reaction
mixtur
contain
reaction
buffer
eurogentec
sera
belgium
total
cellular
rna
extract
nmoll
cgt
tag
tat
gag
tgt
cgt
aca
gcc
tcc
nmoll
gga
ccc
agt
ctt
ccc
ggc
aat
pmoll
probe
tct
gcg
gaa
ccg
gtg
agt
aca
rt
step
perform
min
min
pcr
amplif
compris
cycl
denatur
anneal
extens
abi
fast
realtim
pcr
system
cell
seed
densiti
cell
per
well
cell
cultur
plate
dmem
hygromycin
repliconcontain
cell
follow
overnight
incub
medium
replac
fresh
dmem
without
hygromycin
contain
serial
dilut
test
compound
day
incub
cell
viabil
determin
mean
mtspm
promega
naiv
huh
cell
seed
eightwel
chamber
slide
labtek
ii
nunc
germani
densiti
cellswel
next
day
cultur
inocul
viral
stock
specif
infect
follow
h
incub
inoculum
remov
cell
wash
three
time
incub
h
cell
stain
rabbit
polyclon
antihcv
antibodi
kindli
provid
professor
bartenschlag
univers
heidelberg
germani
secondari
antibodi
alexa
invitrogen
follow
dapi
stain
cultur
visual
use
confoc
laser
scan
microscop
lcsm
leica
microsystem
germani
effect
drug
combin
name
togeth
hcv
proteas
polymeras
inhibitor
evalu
chequerboard
format
use
method
prichard
theoret
addit
effect
calcul
curv
individu
compound
equat
z
x
x
x
repres
inhibit
produc
alon
inhibit
second
compound
alon
z
repres
effect
produc
combin
second
compound
theoret
addit
surfac
subtract
actual
experiment
surfac
result
horizont
surfac
equal
zero
plane
combin
addit
surfac
lie
zero
plane
indic
synergist
effect
combin
surfac
zero
plane
indic
antagon
combin
three
independ
experi
carri
measur
curv
individu
compound
combin
assay
carri
describ
briefli
huh
replicon
carri
neomycin
gene
cultur
consecut
passag
presenc
absenc
antivir
drug
without
addit
cultur
medium
clearanc
phase
next
cell
cultur
absenc
antivir
compound
presenc
rebound
phase
principl
cell
lose
replicon
clearanc
phase
die
rebound
phase
wherea
cell
replicon
complet
clear
abl
surviv
presenc
huh
cell
seed
densiti
cell
per
well
cell
cultur
plate
complet
dmem
mgml
presenc
combin
either
reach
confluenc
cell
trypsin
seed
new
cell
cultur
plate
condit
follow
seven
passag
select
half
cultur
fix
stain
giemsa
remain
cultur
store
use
divers
librari
small
molecul
contain
semisynthet
glycopeptid
antibiot
ie
semisynthet
deriv
teicoplanin
figur
eremomycin
vancomycin
screen
subgenom
hcv
system
genotyp
none
vancomycin
deriv
inhibit
subgenom
hcv
replic
wherea
one
eremomycin
deriv
effect
concentr
cytostat
concentr
data
shown
particular
sever
teicoplanin
aglycon
analogu
found
inhibit
hcv
replicon
replic
three
differ
subgenom
replicon
system
nontox
concentr
tabl
potent
analogu
first
seri
compound
evalu
tabl
valu
rang
sinc
teicoplanin
known
high
bind
affin
serum
protein
evalu
effect
human
serum
antihcv
activ
presenc
human
serum
albumin
increas
valu
observ
data
shown
panel
structur
close
relat
deriv
seri
figur
next
evalu
effect
hcv
replic
molecul
inhibit
hcv
replic
concentrationdepend
manner
among
other
slightli
efficaci
respect
figur
tabl
antivir
activ
select
caus
advers
effect
host
cell
concentr
hcv
replic
inhibit
wherea
host
cell
metabol
slightli
affect
concentr
inhibitori
effect
corrobor
monitor
effect
express
viral
protein
hcv
figur
also
inhibit
vitro
replic
yellow
fever
viru
dengu
viru
type
low
micromolar
concentr
replic
bovin
viral
diarrhoea
viru
anoth
member
famili
flavivirida
antivir
efficaci
combin
ifn
proteas
inhibitor
polymeras
inhibitor
evalu
day
antivir
assay
huh
cell
chequerboard
format
combin
analys
method
prichard
combin
result
addit
antivir
effect
figur
experi
set
studi
whether
abl
clear
repliconcontain
cell
huh
hcv
replicon
huh
cell
treat
four
consecut
passag
proteas
inhibitor
polymeras
inhibitor
either
alon
combin
proteas
polymeras
inhibitor
use
alon
reduc
hcv
rna
replic
tabl
figur
fail
clear
cell
replicon
even
follow
four
consecut
passag
contrast
alon
also
combin
inhibitor
result
effici
inhibit
viral
replic
studi
whether
replicon
resist
hcv
proteas
polymeras
inhibitor
remain
suscept
shown
tabl
prove
equipot
wildtyp
replicon
well
panel
replicon
resist
proteas
inhibitor
nucleosid
polymeras
inhibitor
nonnucleosid
polymeras
inhibitor
replicon
studi
whether
abl
delay
even
prevent
resist
develop
hcv
replicon
proteas
inhibitor
huh
repliconcontain
cell
cultur
seven
consecut
passag
presenc
either
alon
drugresist
replicon
readili
select
assess
passag
howev
combin
coloni
develop
tabl
result
advers
effect
host
cell
sinc
chang
morpholog
densiti
observ
parallel
control
cultur
treat
antivir
molecul
absenc
pressur
none
cultur
also
treat
coloni
develop
passag
combin
thu
complet
clear
cell
replicon
suppress
emerg
drugresist
variant
glycopeptid
antibiot
vancomycin
teicoplanin
wide
use
often
lastresort
treatment
gramposit
bacteri
inhibit
bacteri
cell
wall
biosynthesi
form
noncoval
complex
bacteri
peptidoglycan
common
structur
share
among
glycopeptid
ie
heptapeptid
core
crucial
antibacteri
sheer
size
complex
structur
facilit
numer
chemic
biochem
modif
although
alway
synthesi
analogu
pharmacophor
analysi
reveal
substructur
implic
antihcv
activ
may
reduc
lead
smaller
molecul
delin
substructur
within
glycopeptid
may
serv
focal
point
chemic
modif
analogu
seri
figur
almost
activ
parent
compound
tabl
figur
argu
major
role
teicoplanin
peptid
scaffold
chemic
modif
may
also
help
optim
pharmacolog
properti
class
molecul
chemic
modif
vancomycin
result
exampl
develop
oritavancin
molecul
long
halflif
h
distribut
exampl
limit
oral
avail
glycopeptid
overcom
formul
exampl
vancomycin
liposom
solidst
sinc
neither
virus
mammalian
host
cell
produc
peptidoglycan
mechan
action
antibiot
inhibitori
activ
virus
certainli
differ
definit
mechan
bacteria
aglycon
glycopeptid
antibiot
target
entri
earli
step
replic
cycl
fact
molecul
inhibit
entri
virus
necessarili
mean
mechan
hcv
must
similar
geneticin
exampl
shown
inhibit
pestiviru
releas
replic
translat
even
though
virus
belong
famili
flavivirida
inhibit
two
differ
mechan
demonstr
unlik
case
hiv
coronavirus
inhibit
hcv
replic
postentri
event
inde
molecul
inhibit
replic
hcv
subgenom
replicon
encod
structur
protein
activ
replicon
compar
infecti
hcv
system
furthermor
still
activ
ad
hcvinfect
cultur
whether
inhibit
intracellular
replic
result
direct
interact
viral
protein
mediat
interfer
host
cell
factor
remain
elucid
far
abl
select
drugresist
variant
despit
sever
month
attempt
interestingli
oritavancin
shown
interfer
intracellular
cholesterol
phospholipid
membran
organ
host
cell
lipid
membran
import
hcv
replic
thu
possibl
might
target
cellular
factor
essenti
hcv
replic
ii
influenc
cell
lipid
metabol
way
counteract
hcv
replic
disturb
membran
organ
import
hcv
replic
cycl
subgenom
replicon
model
effici
clear
cell
hcv
replicon
proteas
polymeras
inhibitor
concentr
test
figur
futur
hcv
therapi
consist
combin
two
select
line
aim
studi
combin
effect
either
ifn
hcv
inhibitor
proteas
polymeras
inhibitor
combin
result
overal
addit
antivir
effect
figur
henc
compound
probabl
interfer
mechan
action
select
inhibitor
support
observ
equipot
wildtyp
replicon
replicon
resist
variou
inhibitor
proteas
nucleosid
nonnucleosid
polymeras
delay
prevent
resist
develop
replicon
proteas
inhibitor
importantli
even
month
continu
cultur
presenc
suboptim
concentr
hcv
replicon
reduc
suscept
emerg
barrier
resist
class
compound
might
therefor
high
assum
hcv
quasispeci
equal
divers
vitro
vivo
conclus
aglycon
analogu
teicoplanin
inhibit
vitro
hcv
replic
particular
potent
clear
hepatoma
cell
replicon
explor
relationship
may
lead
develop
highli
potent
inhibitor
hcv
replic
moreov
class
molecul
also
provid
good
tool
obtain
novel
insight
replic
cycl
hcv
cellular
factorsprocess
crucial
viral
replic
work
support
postdoctor
fellowship
research
foundat
flandersfwo
j
p
grant
research
foundat
flandersfwo
chemic
part
work
support
russian
fundament
research
grant
gener
experiment
data
draft
manuscript
j
n
princip
investig
promot
j
p
copromot
coordin
studi
p
e
n
n
p
synthes
provid
compound
test
k
analys
data
help
draft
manuscript
f
z
provid
hcv
infecti
cell
cultur
system
necessari
expertis
implement
system
experiment
setup
author
involv
interpret
data
review
revis
manuscript
intellectu
content
approv
final
version
submiss
